Company profile

Ticker
DNLI
Exchange
CEO
Ryan J. Watts
Employees
Incorporated in
Location
Fiscal year end
SEC CIK

DNLI stock data

(
)

Calendar

6 Aug 19
17 Sep 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 4.2M 4.21M 125.68M 1.2M
Net income -58.34M -38.99M 77.53M -35.37M
Diluted EPS -0.61 -0.41 0.79 -0.38
Net profit margin -1390% -927% 61.69% -2960%
Operating income -62.76M -42.51M 74.72M -37.96M
Net change in cash 23.28M -37.46M 33.47M 10.56M
Cash on hand 62.94M 39.66M 77.12M 43.65M
Annual (USD) Dec 18 Dec 17 Dec 16
Revenue 129.16M NaN NaN
Net income -36.24M -88.19M -86.65M
Diluted EPS -0.39 -5.89 -13.49
Net profit margin -28.06% NaN% NaN%
Operating income -46.37M -90.14M -87.43M
Net change in cash -141.25M 178.52M
Cash on hand 77.12M 218.38M 39.85M

Financial data from company earnings reports

Financial report summary

?
Competition
EisaiMallinckrodtBiogenAstrazenecaRocheShireCytokineticsSanofiAbbVieProthena
Risks
  • Risks Related to Our Business, Financial Condition and Capital Requirements
  • Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
  • Risks Related to Regulatory Approval and Other Legal Compliance Matters
  • Risks Related to Our Reliance on Third Parties
Management Discussion
  • *  Percentage is not meaningful.
  • *  Percentage is not meaningful.
  • Collaboration Revenue. Collaboration revenue was $4.2 million and $8.4 million for the three and six months ended June 30, 2019, respectively, and $1.6 million and $2.3 million for the three and six months ended June 30, 2018, respectively. The increase in the three months ended June 30, 2019 compared to the three months ended June 30, 2018 was due to $3.5 million of revenue recognized under our Sanofi Collaboration Agreement, partially offset by a decrease in revenue recognized under the Takeda Collaboration Agreement of $0.9 million. The increase in the six months ended June 30, 2019 compared to the six months ended June 30, 2018 was due to $7.0 million of revenue recognized under our Sanofi Collaboration Agreement, partially offset by a decrease in revenue recognized under the Takeda Collaboration Agreement of $0.9 million.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: altogether, Dementia, driven, fined, formation, Franc, Frontotemporal, FTD, granule, half, ineligible, Intraperiod, judge, jury, rheumatoid, shifting, supposed, undisclosed
Removed: Antitrust, bankruptcy, calculating, comprising, cure, deposit, exact, exercisable, fifty, fourth, hindsight, insolvency, insolvent, liquidity, myeloid, opt, opted, optimized, remedy, requisite, standoff, unanimously